Metropolitan Anchor Hospitals
鈥
鈥
Sen. Lamar Alexander (R-TN), chairman of the Senate Committee on Health, Education, Labor and Pensions, today said he and committee Ranking Member Patty Murray (D-WA) had reached an agreement on legislation to fund cost-sharing reduction payments for two years and provide states some flexibility in鈥
The AHA and seven other national organizations this weekend urged congressional leaders to 鈥渢ake action now to fund cost-sharing reduction benefits for the millions of Americans who depend on this critical program.鈥 The White House announced last week that it will stop making CSR payments鈥
The Health Resources and Services Administration has announced that 340B Drug Pricing Program hospitals in areas affected by recent natural disasters can immediately enroll in the program instead of waiting for the normal registration period. 鈥淗RSA recognizes that circumstances surrounding disaster鈥
The Trump administration will stop making cost-sharing reduction payments to health insurers, the White House announced last night. Insurers use the federal payments to reduce out-of-pocket costs for low-income individuals purchasing coverage through the Health Insurance Marketplaces. The鈥
The House Energy and Commerce Subcommittee on Oversight and Investigations today held a hearing examining how covered entities use the 340B Drug Pricing Program. Established by Congress in 1992, the program mandates that drug manufacturers provide outpatient drugs to eligible health care鈥
As Congress turns to tax reform, a new analysis prepared by Ernst & Young for the AHA finds that hospitals鈥 and health systems鈥 community benefit activities outweigh the value of their federal tax exemption by a factor of 11 to one. According to the report, non-profit hospitals in 2013, the鈥
The latest report from a group financed and backed by the pharmaceutical industry 鈥渃ontinues to misrepresent鈥 the 340B Drug Pricing Program and its 鈥渟uccessful 25-year history of helping hospitals stretch scarce financial resources to expand and improve access to lifesaving prescription drugs and鈥
The latest report from AIR340B, a group financed and backed by the pharmaceutical industry, continues to misrepresent a program with a successful 25-year history of helping hospitals stretch scarce financial resources to expand and improve access to lifesaving prescription drugs and comprehensive鈥
Fifty-seven senators Friday urged the Centers for Medicare & Medicaid Services (CMS) to 鈥渃arefully consider stakeholder feedback鈥 before the agency finalizes its proposal to reduce Medicare Part B payment for drugs acquired through the 340B Drug Pricing Program. 鈥淭he long-term success of the鈥